|
|
|
ix | |
|
Section I - Cells and cell surface receptors |
|
|
|
T cells - overview - update |
|
|
1 | (6) |
|
|
|
|
|
Pathways of T-cell costimulation |
|
|
7 | (16) |
|
|
|
|
|
|
|
|
|
23 | (8) |
|
|
|
B-cell antigen receptor signaling and autoimmunity |
|
|
31 | (14) |
|
|
|
|
|
|
|
|
|
|
|
Macrophages in rheumatoid arthritis |
|
|
45 | (18) |
|
|
|
|
|
|
|
63 | (16) |
|
|
|
|
|
|
|
79 | (6) |
|
|
|
|
|
Cell contact dependence of inflammatory events |
|
|
85 | (20) |
|
|
|
|
|
|
|
Toll-like receptors: possible targets for novel treatments for rheumatoid arthritis |
|
|
105 | (16) |
|
|
|
|
|
Cadherin-11 mediates synovial lining organization: a new therapeutic target in inflammatory arthritis |
|
|
121 | (12) |
|
|
|
|
|
Section II - Cytokines, chemokines and other effector molecules |
|
|
|
|
|
133 | (16) |
|
|
|
|
|
|
|
149 | (10) |
|
|
|
|
|
|
|
159 | (16) |
|
|
|
|
|
Biology of interleukin-15 |
|
|
175 | (10) |
|
|
|
|
|
|
|
Interleukin-17: a new target in arthritis |
|
|
185 | (10) |
|
|
|
|
|
|
|
The role of interleukin-18 in inflammation |
|
|
195 | (16) |
|
|
|
|
|
211 | (14) |
|
|
|
|
|
The biology of human interleukin-32 |
|
|
225 | (6) |
|
|
|
|
|
|
|
231 | (20) |
|
|
|
|
|
|
|
|
|
251 | (14) |
|
|
|
|
|
Update: inflammatory, angiogenic, and homeostatic chemokines and their receptors |
|
|
265 | (20) |
|
|
|
|
|
Section III - Transcription factors and signaling molecules |
|
|
|
New developments in NF-κB |
|
|
285 | (12) |
|
|
|
|
|
|
|
Roles of the JAK-STAT signaling pathways in rheumatoid arthritis |
|
|
297 | (8) |
|
|
|
|
|
|
|
|
|
Suppressor of cytokine signaling (SOCS) proteins as therapeutic targets in rheumatoid arthritis |
|
|
305 | (22) |
|
|
|
|
|
|
|
Wnt signaling for targeted therapies in rheumatology |
|
|
327 | (2) |
|
|
|
|
|
|
|
Section IV - Inflammatory mediators and matrix molecules |
|
|
|
Inflammatory mediators: update on cyclooxygenases and prostaglandin synthases |
|
|
329 | (10) |
|
|
|
|
|
|
|
Complement and pregnancy loss |
|
|
339 | (14) |
|
|
|
|
|
Matrix metalloproteinases |
|
|
353 | (14) |
|
|
|
|
|
|
|
MMPs and ADAMs as targets for therapies in arthritis |
|
|
367 | (18) |
|
|
|
|
|
|
|
Section V - Targeted therapies in human and experimental rheumatic diseases |
|
|
|
Update on proinflarnmatory cytokine blockade in rheumatoid arthritis |
|
|
385 | (7) |
|
|
|
Targeting interleukin-1 in rheumatic diseases |
|
|
392 | (9) |
|
|
|
|
|
Update on targeted therapy in psoriatic arthritis |
|
|
401 | (12) |
|
|
|
|
|
413 | (6) |
|
|
|
|
|
|
|
419 | (6) |
|
|
|
|
|
|
|
425 | (10) |
|
|
|
Update - systemic lupus erythematosus |
|
|
435 | (14) |
|
|
|
|
|
|
|
449 | (18) |
|
|
|
|
|
|
|
|
|
467 | (18) |
|
|
|
TNF blockade in orphan rheumatic diseases |
|
|
485 | (12) |
|
|
|
Haralampos M Moutsopoulos |
|
|
Overview of the safety of TNF inhibitors |
|
|
497 | (12) |
|
|
|
|
|
Anti-CD20 to further targeted therapies in rheumatology |
|
|
509 | (18) |
|
|
|
|
|
Targeting B-lymphocyte stimulator (BLyS) in immune-based rheumatic diseases: a therapeutic promise waiting to be fulfilled |
|
|
527 | (16) |
|
|
|
Anti-CD3 antibody - a history of successful immune interventions |
|
|
543 | (10) |
|
|
|
|
|
|
|
553 | (8) |
|
|
|
Clinical targeting of interleukin-15 |
|
|
561 | (8) |
|
|
|
|
|
Clinical prospects of MAPK inhibitors |
|
|
569 | (12) |
|
|
|
|
|
Clinical prospects of NF-κB inhibitors to further targeted therapies in rheumatology |
|
|
581 | (20) |
|
|
|
|
|
|
|
Outcomes assessment in rheumatic disease |
|
|
601 | (16) |
|
|
|
|
| Index |
|
617 | |